-
Pengyang Yiliao Raises Series B+ Funds for Cardiovascular Product Development
•
Pengyang Yiliao, a Beijing-based developer and manufacturer of cardiovascular technology, has reportedly raised “tens of millions” of renminbi in a Series B+ financing round. The investors included Suzhou Wuzhong Economic and Technological Innovation Investment Partnership Limited and Suzhou Wuzhong Jingkai Intelligent Manufacturing Investment Partnership Limited. The proceeds will be used…
-
Zhejiang Medicine’s ARX788 Shows Positive Results in Breast Cancer Study
•
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) has announced positive results from a Phase II/III clinical study for its sARX788, an anti-HER2 monoclonal antibody-AS269 conjugate, in the treatment of breast cancer. The study, which assessed the drug’s efficacy and safety in HER2-positive local advanced or metastatic breast cancer, reached its…
-
Glowe Raises Series A+ Funding to Expand AIGC in Mental Health
•
Glowe, an online psychological consultation platform based in Guangdong, has reportedly raised “tens of millions” of renminbi in a Series A+ financing round. The round was led by FreesFund, with proceeds intended to ramp up the application of Artificial Intelligence Generated Content (AIGC) in the platform’s services. Glowe: Platform Overview…
-
Geneus Tech Secures Funding for Gseq500 Gene Sequencer Production
•
Geneus Tech, a Shenzhen-based developer and manufacturer of gene sequencers, has reportedly raised an undisclosed amount of money in a Series B+ financing round. The round was led by GF Xinde Investment and a private equity fund initiated by Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244). The proceeds will be…
-
Alphamab Oncology Partners with Stemirna for BsAb and mRNA Vaccine Development
•
China-based Alphamab Oncology (HKG: 9966) has announced a strategic partnership with Shanghai-based mRNA drug developer Stemirna Therapeutics Co., Ltd. The collaboration focuses on the clinical development of bispecific antibodies (BsAbs) and mRNA vaccines, with an initial focus on the combination of KN052 and SWP1001. No financial details of the partnership…
-
CanSino Biologics’ Inhalable COVID-19 Vaccine Gets EUA in Indonesia
•
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received emergency use authorization (EUA) for its inhalable recombinant novel coronavirus vaccine (adenovirus type 5 vector) in Indonesia. This marks a significant milestone in the global fight against COVID-19, as the company expands its vaccine’s availability to another…
-
BeiGene Reports Outstanding Q4 and Full-Year 2022 Financial Results
•
BeiGene, Ltd. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has released financial results for the Q4 and full-year 2022 periods, along with recent business highlights and upcoming milestones. Revenues reached USD 380.1 million in Q4, up 72.3%, and USD 1.4 billion for the full 12 months, up 97.9%. CEO John Oyler…
-
Viatris Reports Q4 2022 Results, Highlights China Growth
•
US-based generics giant Viatris Inc. (NASDAQ: VTRS) has released its Q4 2022 financial report. The firm reported a 2% year-on-year (YOY) fall in net sales to USD 16.2 billion. The decrease was partly attributed to the USD 3 billion sale of Viatris’ biosimilars business to India-based Biocon Biologics Ltd, a…
-
China Performs First AB-BNCT Procedures Outside Japan
•
The first accelerator-based boron neutron capture therapy (AB-BNCT) procedures have been performed in China by the Neuboron Medical Group at Xiamen Humanity Hospital (XHH). This marks a significant milestone as it represents the first time human patients have been treated with AB-BNCT technology outside of Japan. Trial Details and ResultsA…
-
HutchMed Reports 2022 Financial Results with Revenue Growth
•
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has released its financial results for the year ended December 31, 2022, alongside updates on key clinical and commercial developments. Revenues for the year ending December 31, 2022, were USD 426.4 million, compared to USD 356.1 million in 2021, primarily driven by…
-
3SBio’s Nalfurafine Tablets Accepted for Review by NMPA for Chronic Liver Disease
•
China-based 3SBio Inc. (HKG: 1530) has announced that a clinical trial filing for its nalfurafine oral disintegrating tablets (TRK-820) for the improvement of pruritus in patients with chronic liver disease has been accepted for review by the National Medical Products Administration (NMPA). This follows the previous acceptance for review of…
-
3SBio Terminates Distribution Agreement with AstraZeneca for Byetta
•
China-based 3SBio Inc. (HKG: 1530) has announced the termination of a distribution agreement with UK major AstraZeneca (AZ, NASDAQ: AZN), effective from December 31, 2023, concerning AstraZeneca’s Byetta (exenatide). The two companies previously entered into a licensing deal focusing on type 2 diabetes therapies, including Byetta and Bydureon (exenatide microspheres).…
-
JW Therapeutics Initiates Clinical Study for JWATM214 in Advanced Hepatocellular Carcinoma
•
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its pipeline candidate JWATM214 in patients with advanced hepatocellular carcinoma (HCC). This first-in-human study is designed to evaluate the safety and tolerability, determine the recommended Phase II dose (RP2D), and evaluate the pharmacokinetic profile and preliminary…
-
FibroGen Reports Q4 2022 Financial Results with Revenue Growth
•
US-based FibroGen Inc. (FGEN) has released its Q4 2022 financial results. The company reported global revenues of USD 34.4 million in Q4, up from USD 16.4 million a year ago. For the 12 months, revenues reached USD 140.7 million, down from USD 235.3 million in 2021, when revenues were boosted…
-
China Issues New Ethical Review Measures for Life Sciences and Medical Research
•
The National Health Commission, Ministry of Education, Ministry of Science and Technology, and National Administration of Traditional Chinese Medicine have released the “Measures for Ethical Review of Human Life Sciences and Medical Research.” This document establishes comprehensive guidelines to ensure ethical standards are met in all life science and medical…
-
Bayer Reports 2022 Sales Growth, Highlights New Drug Performances
•
Germany-based Bayer (ETR: BAYN) released its 2022 annual report this week, revealing a global sales growth of 8.7% year-on-year (YOY) in constant exchange rate and portfolio-adjusted terms, reaching EUR 50.7 billion (USD 53.8 billion). The report highlights significant performances across its business segments, particularly in Pharmaceuticals and Consumer Health. Pharmaceuticals…
-
China’s NRDL Update and Expansion of ‘Dual Channel’ Drug Access
•
The latest update to China’s National Reimbursement Drug List (NRDL) was implemented from March 1, 2023. Alongside this, Shanghai released a list of 383 drugs that will be involved in the “dual channel” management system. This initiative allows insured patients in Shanghai to purchase these drugs at designated retail pharmacies…
-
China’s State Council Unveils Plan for TCM Revitalization and Development
•
The State Council has released the “Traditional Chinese Medicine (TCM) Revitalization and Development Major Projects Implementation Plan.” This comprehensive document outlines a strategic approach to enhance the role of TCM in China’s health, economic, scientific, technological, cultural, and ecological landscape. TCM’s Strategic ImportanceThe document emphasizes that TCM is a vital…
-
Topchoice Medical to Acquire 19% Stake in Heren Health for $72.2M
•
China-based Topchoice Medical Investment Corp., (SHA: 600763) a leading medical service group, is set to acquire a 19% stake in compatriot firm Heren Health Co., Ltd, a smart medicine solutions provider for hospitals and governments. The transaction is valued at RMB 501 million (USD 72.2 million). The aim is to…
-
Eluminex Biosciences Closes $40M Series B for Ophthalmic Innovations
•
China-based ophthalmic biotech Eluminex Biosciences (Suzhou) Ltd has announced the closure of a Series B financing round, raising over USD 40 million. The funds will be directed towards clinical studies in biosynthetic cornea and the development of several innovative ophthalmic drugs. The financing round was led by Cenova Ventures, with…
